Primary outcome | | | | |
VAP | 39 (23.2) | 14 (16.7) | 25 (29.8) | 0.07 |
Secondary outcomes | | | | |
VAP IDR | 18 | 11.4 | 25.6 | <0.01 |
GNB-VAP | 30 (17.9) | 9 (10.7) | 21 (25) | 0.03 |
MDR-VAP | 22 (13.1) | 6 (7.1) | 16 (19) | 0.04 |
VAP due to Acinetobacter baumannii | 13 (7.7) | 2 (2.8) | 11 (13.1) | 0.02 |
VAP due to Staphylococcus species | 9 (5.4) | 5 (6) | 4 (4.8) | 1.0 |
VAP during the 10-day prophylaxis | 28 (16.7) | 9 (10.7) | 19 (22.6) | 0.06 |
VAP post 10-day prophylaxis | 11 (6.5) | 5 (6) | 6 (7.1) | 1.0 |
VAP following VAT | 6 (3.6) | 4 (4.8) | 2 (2.4) | 0.68 |
VAT IDR | 5.3 | 4.1 | 6.6 | <0.01 |
VAT | 11 (6.5) | 5 (6) | 6 (7.1) | 1.0 |
GNB-VAT | 11 (6.5) | 5 (6) | 6 (7.1) | 1.0 |
MDR-VAT | 9 (5.4) | 4 (4.8) | 5 (6) | 1.0 |
VAT due to Acinetobacter baumannii | 5 (3) | 2 (2.4) | 3 (3.6) | 1.0 |
VAT during the 10-day prophylaxis | 7 (4.2) | 2 (2.4) | 5 (6) | 0.44 |
Airway colonisation | 34 (20.2) | 16 (19) | 18 (21.4) | 0.85 |
During the 10-day prophylaxis | 22 (13.1) | 6 (7.1) | 16 (19) | <0.01 |
After the 10-day prophylaxis | 12 (7.1) | 10 (11.9) | 2 (2.4) | <0.01 |
Due to GNB | 33 (19.6) | 15 (17.9) | 18 (21.4) | 0.70 |
Due to MDR | 28 (16.7) | 13 (15.5) | 15 (17.9) | 0.84 |
ICU mortality | 54 (32.1) | 25 (29.8) | 29 (34.5) | 0.62 |
ICU stay days | 13.5 (7–28) | 16.5 (7–29.7) | 13 (6.25–24.7) | 0.31 |
Hospital mortality | 60 (35.7) | 29 (34.5) | 31 (36.9) | 0.87 |
Hospital stay days | 20 (12–30) | 23 (12–30) | 19 (12.2–30) | 0.38 |
MV days¶ | 12 (5–21) | 13.5 (5–24.5) | 9 (5–18.7) | 0.26 |
MV days before first episode of VAI | 7 (4–12.2) | 10 (7–15) | 6 (4–10) | 0.01 |
MV days before first episode of VAP | 6 (4–12) | 10 (5.5–16.5) | 4 (3.5–10.5) | 0.07 |
MV-free days | 1 (0–3) | 1 (0–3) | 1 (0–3) | 0.90 |
Days without systemic antibiotic exposure | 1 (0–5) | 2.5 (0–5) | 0.5 (0–3) | 0.06 |
Tracheostomy | 76 (45.2) | 43 (51.2) | 33 (39.3) | 0.16 |